Innovation and business
At the Crick, we believe that science can deliver advances in health, economic growth and global wellbeing.
Our researchers are encouraged to think about the real-world impact of their work, with tailored support to help them scale ideas through strategic partnerships and innovation pathways.
Get in touch with the Innovation and Business team to find out how you can work with us.
We support researchers to develop scientific discoveries into health treatments, diagnostics and technologies, by providing funding, expertise, intellectual property guidance and connections to key innovation partners.
We collaborate with industry and investors to advance Crick research and attract new R&D funding and partnership opportunities.
We develop opportunities from the Crick’s infrastructure and expertise to accelerate scientific innovation across the UK and globally. We contribute to the UK’s life sciences ecosystem by supporting start-ups, offering bespoke lab space and promoting London as a global biosciences hub.
“The ultimate goal for any scientist - is to see their work translated into something that will impact people's lives.
We provide funding and expertise to help translate scientific research into innovative treatments and technologies.
Find out more
We bring together world-class discovery science and pharmaceutical R&D expertise.
Find out more
We build a culture that fosters and celebrates innovation and entrepreneurship.
Find out more
We identify, protect, develop and commercialise intellectual property arising from research at the Crick.
Find out more
George Kassiotis, head of the Crick’s Retroviral Immunology Laboratory, co-founded Enara in 2019 with the support of the Crick’s Translation team and went on to win the Crick’s Sir David Cooksey Prize in Translation in 2018.
The company was initially focussed on dormant fragments of retroviral DNA that make up around 8% of our genome and have been left behind by retroviruses that infected our ancestors.
A nationwide team of universities, hospitals and industry led by the Crick and The Royal Marsden NHS Foundation Trust have launched a new platform to understand immunotherapy response and side effects in cancer.
Group Leader at the Crick, Simon Boulton, co-founded Artios in 2016, a spin-out from Cancer Research UK’s Commercial Partnerships, where he is now VP of Science Strategy. Artios develops cancer treatments that target DNA damage response pathways.
